Explore the profound impact of music therapy with Professor Lee Anna Rasar on the LDN Radio Show. Discover how adapted songs aid anger management, how harmonica playing enhances respiratory function, and how melodic intonation therapy assists stroke patients. Learn about music's role in sleep induction, dementia care, and Parkinson's gait training, showcasing its neuroscience-based approach.

Book for the Live Zoom webinar, $20 including the recording

With Lee Anna Rasar, Professor of Music Education/Therapy,

titled “Dancing in the Rain: Music to Complement LDN.”

for medical professionals and patients

28th April at 11:00 a.m. Central Time (5:00 p.m. UK Time).

1-hour presentation followed by a 1-hour live Q&A

register at https://linktr.ee/ldnrt

Low dose naltrexone (LDN) shows promise in treating autoimmune diseases and cancers. Dr. Stephanie Werner shares insights on LDN's effectiveness in managing inflammation and enhancing patient outcomes, particularly in women's health issues like polycystic ovary syndrome and pregnancy challenges. The importance of diet and avoiding inflammatory foods is discussed, along with personal responsibility in healthcare and LDN's potential in managing chronic conditions.

Low-dose naltrexone (LDN) is highlighted as a supportive treatment in oncology, enhancing other therapies rather than acting alone. It helps regulate the immune system, calms microglia, and alleviates symptoms like pain and fatigue. LDN's low toxicity and potential to improve quality of life are emphasized, along with its evolving role in cancer therapies and immune modulation.

Low-dose naltrexone (LDN) is discussed as a treatment for chronic illnesses, focusing on its effectiveness and dosing protocols. Experts highlight the importance of collaboration among healthcare providers and the need for more research and awareness. They address misconceptions, potential insurance coverage, and share patient experiences, emphasizing personalized care in managing chronic conditions. The show invites further inquiries from the audience.

LDN treatment involves specific dosing strategies and patient experiences, particularly for conditions like multiple sclerosis and restless leg syndrome. Timing of medication is crucial, and the discussion highlights the rising prevalence of autism, potential links to environmental toxins, and dietary influences. Families face challenges in managing these conditions, emphasizing the need for ongoing communication between practitioners and patients as understanding of LDN's applications evolves.

Dr. Pamela Smith explores the benefits of low dose naltrexone (LDN) and therapeutic plasma exchange (TPE) for treating toxins and autoimmune diseases. She discusses the rising toxicity in patients and how combining TPE with LDN and nutrients can enhance health outcomes. The importance of personalized treatment plans and the role of inflammation in chronic diseases are highlighted, along with insights on managing medication tolerance and the need for ongoing research.

Dr. Phil Boyle explains how low-dose naltrexone can effectively treat infertility and recurrent miscarriage. He outlines the clinical criteria for its use and shares patient experiences. Maintaining treatment during pregnancy is crucial for better outcomes. The discussion also covers naltrexone's potential benefits for postpartum depression and the significance of endorphin levels in health. Dr. Boyle concludes with a mention of a new publication in restorative reproductive medicine.

Kallos from Napal shared her expereince of LDN and how it helped her get her life back. She has UCTD, Vitiligo and PCOS

Kallos from Nepal shared her inspiring experience with Low-Dose Naltrexone (LDN) and how it has played a crucial role in helping her regain control of her life. Living with conditions such as Undifferentiated Connective Tissue Disease (UCTD), vitiligo, and Polycystic Ovary Syndrome (PCOS) had made daily life challenging for her.

Before starting LDN, Kallos struggled with various symptoms that significantly impacted her quality of life, including fatigue, skin issues, and hormonal imbalances. However, after discussing her options with her healthcare provider, she decided to try LDN as a part of her treatment plan.

Since incorporating LDN into her routine, she has noticed remarkable improvements in her overall well-being. Kallos feels more energetic, her skin condition has stabilized, and her symptoms of PCOS have become more manageable. She emphasizes how LDN has not only improved her physical health but has also positively affected her mental health, allowing her to engage more fully with her daily activities and reclaim her life.

Taran from the United States shares her journey with Ehlers-Danlos Syndrome (EDS) and Postural Orthostatic Tachycardia Syndrome (POTS), which began in 2015 when she suddenly passed out at work, becoming bedridden for six months. Despite being very active beforehand, she was left confused and distressed. After researching online and consulting with a cardiologist, Taran received diagnoses for POTS and EDS.

For several years, they underwent a trial-and-error approach to treatment. In September 2024, Taran's mother discovered low-dose naltrexone (LDN) as a potential treatment, leading Taran to a primary care physician specializing in EDS. Nervously, she started LDN at a low dose and experienced significant pain and fatigue relief within days. After finding their optimal dose at 4.5 mg, Taran described the medication as a life-changing experience.

Reflecting on her childhood, Taran recalls having eczema, random rashes, and food sensitivities, which went unnoticed due to their active lifestyle. Overall, she express gratitude for LDN and its impact on managing her symptoms.

Barb from Canada shares her 26-year journey with fibromyalgia, which began with chronic pain and a lengthy struggle for a diagnosis. Initially, she explored various treatments, including conventional medications like Oxycontin and alternative therapies, but found limited relief.

After learning about Low Dose Naltrexone (LDN) from the fibromyalgia community, she sought a doctor willing to prescribe it. After changing family doctors, Barb encountered a new physician who did not believe in fibromyalgia and refused to prescribe LDN. However, through the LDN Research Trust, she found a supportive doctor who offered remote consultations. Since starting LDN in April, Barb experienced remarkable improvements in energy and quality of life within three weeks, allowing her to engage in activities she had long avoided. Her transformation has surprised both her and her family, leading others to inquire about her treatment.